ST. LOUIS, MO--(Marketwire - September 24, 2009) -
Mobius Therapeutics, LLC ™ has been
awarded a research grant from the National Institute on Deafness and other
Communication Disorders (NIDCD) to study its investigational procedure,
selective Photodynamic Myringotomy (PDM).
PDM is a procedure where the tympanic membrane (ear drum) is treated with a
specially stained anti-scarring agent. The stained tissue is then exposed
to a specially tuned laser, designed to be absorbed only at the site of the
stain. The procedure treats ear infections by opening the membrane to
ventilate and drain the ear. The anti-scarring agent slows the healing
process which allows the ear to stay ventilated, while eliminating the need
for pressure equalization tubes and the associated surgery.
"The potential of PDM is enormous," said Ed Timm, President of Mobius
Therapeutics. "Otitis media is the single most common reason for a child
to visit the doctor. In the USA alone, bilateral myringotomy with tubes
accounts for an estimated 2,000,000 surgeries each year on children under
the age of 16. The ability to replace an anesthetized hospital surgical
procedure with a single, painless office procedure would be welcomed by
both children and parents."
"This grant will allow Mobius to achieve measurable milestones," Timm
continued. "The rapid issuance of broad patent protection compelled us to
accelerate the development of PDM. We are grateful to NIDCD and corporate
supporters that have made this development possible."
About Mobius Therapeutics™:
Mobius Therapeutics, LLC™ is an early stage venture focused on glaucoma
and otologic surgery solutions. Its first product, Trabomycin™, is a
system for delivering antifibrotic agents in glaucoma surgery. It is
awaiting regulatory approval, with additional product applications in
earlier stages of development. Mobius relocated from Atlanta to St. Louis
in July 2007 and is a portfolio company of The Incubation Factory of St.